Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX, Pembrolizumab, Cyclophosphamide, and SBRT in Locally Advanced Pancreatic Cancer
NCT02648282Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2016
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of GVAX pancreatic cancer vaccine, pembrolizumab in pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2016; status: completed.
02
Drugs
GVAX pancreatic cancer vaccinepembrolizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02648282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648282.